Skip to main
VTVT

vTv Therapeutics (VTVT) Stock Forecast & Price Target

vTv Therapeutics (VTVT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

vTv Therapeutics Inc is advancing its clinical pipeline with the lead candidate, cadisegliatin (TTP399), positioned as a unique late-stage therapy for type 1 diabetes, which could enhance its market appeal. Positive momentum in the company’s valuation is underscored by a raised risk-adjusted DCF valuation reflecting an increase in estimated peak market penetration from 20% to 25%. The company's ongoing studies, including the successful progression of the CATT1 trial, along with insights gained from Phase 2 trials of similar therapeutics, bolster confidence in the safety and efficacy of its pipeline, suggesting a promising outlook for both cadisegliatin and other candidates.

Bears say

vTv Therapeutics Inc's stock presents a negative outlook primarily due to the substantial clinical risks associated with its lead candidate, cadisegliatin (TTP399), which remains in late-stage development but faces challenges such as potential safety findings and efficacy concerns that have not been observed in earlier studies. The historical performance of first-generation glucokinase activators, which faced significant issues including excess hypoglycemia and diminishing glycemic benefits over time, raises further doubts about the long-term viability of vTv's approach in a competitive market. Additionally, the overall failure of a large percentage of adults with type 1 diabetes to achieve recommended glycemic control suggests a difficult therapeutic landscape, diminishing the prospects for successful market adoption of vTv's drug candidates.

vTv Therapeutics (VTVT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About vTv Therapeutics (VTVT) Forecast

Analysts have given vTv Therapeutics (VTVT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, vTv Therapeutics (VTVT) has a Strong Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

vTv Therapeutics (VTVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.